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109The main ﬁnding of the authors is that low implantation depth is
associated with clinically signiﬁcant new conduction disturbances and
permanent pacemaker implantation. Although this result was previ-
ously reported by our team (2), the authors should be congratulated
because the statistical power of their study is much better than ours (89
vs. 34 patients). However, the methodology for measuring the primary
endpoint (i.e., the implantation depth of the stent with multidetector
computed tomography), raises some questions. Indeed, the authors
explained at the end of theMethods section that “the distance from the
stent frame inﬂow to the aortic annulus (most basal insertion of the
native aortic leaﬂets) was measured.”A proper assessment of the native
annulus beforeTAVR is already a difﬁcult and a still debated challenge;
therefore, a proper assessment after TAVR seems very difﬁcult or
unfeasible. Indeed,whenwemade thesemeasurements in our study (2),
we clearly noted that post-implantation multi-detector computed to-
mography implies a complexmixture of artifacts associated with native
calciﬁcations and stent frame, particularly at the most basal insertion of
thenative aortic leaﬂets,which is not visible exceptwhen the stent frame
is implanted in a high position. This is the reasonwhy the implantation
depth was evaluated in our study with reference to the ﬂoor of the si-
nuses of Valsalva.
Because this endpoint reﬂects the main result of their study, I
think that the authors should precisely state, with a dedicated
ﬁgure, the methodology used to measure the depth of implantation
to ensure good reproducibility and comparability with previous and
future studies on this interesting topic.
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Reply
Reply: Looking for the Native Annulus
After Transcatheter Aortic Valve
Replacement?
We thankDr. Caudron for his interest in our paper (1) that evaluated
post-deployment geometry and its impact on conduction distur-
bances, hemodynamic performance, and paravalvular regurgitation.
We have also readwith great interest hismany previous contributions
to the ﬁeld. Dr. Caudron raises concerns regarding the difﬁculty inevaluating the location of the aortic annulus/aortic valve ventricular
plane on post–transcatheter aortic valve implantation (TAVI)
multidimensional computed tomography (CT) imaging and raises
questions as to the strength of the ﬁndings of our study. In fact, Dr.
Caudron implies that even the native annulus may not be repro-
ducibly evaluated on pre-procedural CT: “Aproper assessment of the
native annulus before TAVI is already a difﬁcult and still debated
challenge.” We respectfully disagree with this sentiment. We and
other groups (2–4) have for the last 5 years consistently shown that
the basal ring and annular geometry can be evaluated in a granular and
reproducible fashion prior to TAVI. These 3-dimensional mea-
surements of the annulus have been shown to display high intraclass
correlation coefﬁcients in multiple studies and have received
consensus support to be used to assist transcatheter heart valve se-
lection. Importantly, these measurements have not only been
conﬁrmed to be reproducible, they have also been shown to be
invaluable in guiding transcatheter heart valve sizing and have
allowed the improvement in TAVI-related clinical outcomes (5,6).
With regard to the issue of localization of the annular plain
on post-TAVI imaging, we agree that with only post-TAVI CT
imaging this is very difﬁcult and would undoubtedly suffer from
reproducibility issues. However, unlike in Caudron et al. (7), we
were not limited to post-TAVI CT imaging but rather had both pre-
and post-transcatheter aortic valve replacement CT imaging for all
cases. The baseline CT imaging prior to TAVI provided us an
important mask to allow for the identiﬁcation of the aortic valve
ventricular plane on the pre-transcatheter aortic valve replacement
CT exam and to colocalize it on the post-TAVI CT. Although we
did not perform formal reproducibility analyses, as there was only 1
reader of all of these studies, we strongly feel that the methodological
differences in our study with pre- and post-TAVI CT imaging are
real strengths of our analysis and afforded us a unique opportunity to
perform the measurements and analyses presented in our paper (1).
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Is Time of Renal Hypoperfusion an
Important Variable in Determining
Response to Renal Artery
Revascularization?
The CORAL (Cardiovascular Outcomes in Renal Atherosclerotic
Lesions) trial found that stent implantation did not provide any
beneﬁt beyond optimal medical therapy in the occurrence of death or
adverse cardiovascular or renal events in patients with moderately
severe atherosclerotic renal artery stenosis (1). There was a modest,
consistent difference in systolic blood pressure favoring the stent
group, but this did not result in a decrease in adverse clinical out-
comes. These ﬁndings are consistent with the ASTRAL (Angio-
plasty and Stenting for Renal Atherosclerotic Lesions) trial (2) and
the STAR (Stent Placement and Blood Pressure and Lipid-
Lowering for the Prevention of Progression of Renal Dysfunction
CausedbyAtheroscleroticOstial Stenosis of theRenalArtery) trial (3).
Over the years, studies of renal artery intervention have been
criticized for small sample size, the use of angioplasty alone rather
than stenting, high treatment-crossover rate, and enrollment of
patients with renal artery lesions that were not hemodynamically
signiﬁcant. CORAL is the largest study of renal artery intervention
and anticipated all of these potential criticisms. Even though the
threshold for enrollment in CORAL was lowered to include ste-
nosis of 60%, a subgroup analysis limited to patients with
stenosis 80% did not show any beneﬁt to stent implantation.
Why have the clinical trials of stenting of atherosclerotic renal
artery stenosis failed to show improved clinical outcomes? One var-
iable that might play an important role in determining the beneﬁt of
revascularization is the time of renal hypoperfusion. In the 2-kidney-
1-clip model, abrupt onset of decreased renal perfusion is associated
with renin-angiotensin system activation, leading to sodium and
water retention. Over time, the renin-angiotensin system returns to
baseline levels and the intact normal kidney compensates to excrete
sodium and water by pressure natriuresis (4). Transient activationof the renin-angiotensin system leads to elevated oxidative stress,
sympathoadrenergic activation, and impaired vasoactive responses
within both the kidney and the systemic microcirculation (5).
Moreover, animal studies show that persistent ischemia leads to
irreversible kidney damage and development of a chronic kidney
disease phenotype (6). Similar renal damage is seen in humans; the
majority of patients with renal artery stenosis have renal parenchymal
changes including interstitial ﬁbrosis, tubular atrophy, glomerulo-
sclerosis, periglomerular ﬁbrosis, and a variety of arteriolar abnor-
malities (7). Finally, there is evidence that short-term elevation in
angiotensin II levels can accelerate the development of atherosclerosis
and lead to changes in the arterial wall that persist even after angio-
tensin levels return to baseline (8,9). It is unclear to what extent, if
any, that these adverse renal and vascular effects respond to
revascularization.
Data from animal models suggest that renal parenchymal
damage and aortic atherosclerotic changes begin soon after renal
hypoperfusion. These effects worsen over time and many of the
changes are irreversible. Further studies are needed to determine
whether there is a “window of time” in humans during which
revascularization is beneﬁcial and whether it can be identiﬁed with
biomarkers or renal imaging.
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